Company

Novo Nordisk

NYSE:NVO

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

226 stories · page 10 of 12

Pharma & Biotech

Arecor's novel drug formulations could help cut burden on hospitals

By Proactive 15/12/2023

Pharma & Biotech

LifeMD shares rise on Medifast deal for new GLP-1 weight loss programmes

By Proactive 13/12/2023

Pharma & Biotech

Novo Nordisk: From diabetes to weight loss to obesity preventions

By Proactive 05/12/2023

Pharma & Biotech

Novo Nordisk to invest over US$2bn to expand obesity drug production in France

By Proactive 24/11/2023

Pharma & Biotech

Weight loss drugs Wegovy and Zepbound to debut in pill form

By Proactive 17/11/2023

Pharma & Biotech

Catalent doubles down on full year outlook as preliminary 1Q earnings beat estimates

By Proactive 15/11/2023

Pharma & Biotech

Novo Nordisk's better-than-expected Wevgovy results to have knock-on effect for weight loss drug makers

By Proactive 13/11/2023

Pharma & Biotech

Wegovy predicted to be huge as weight benefits confirmed

By Proactive 13/11/2023

Pharma & Biotech

Novo Nordisk unveils US$6bn investment plans

By Proactive 10/11/2023

Pharma & Biotech

Novo Nordisk to release clinical update on star drug Wegovy

Results from the SELECT study will be presented at the American Heart Association (AHA) conference on November 11.

By Proactive 03/11/2023

Pharma & Biotech

Novo Nordisk shares higher on bumper Wegovy boost

By Proactive 02/11/2023

Pharma & Biotech

Week ahead: Apple, Novo Nordisk, Pfizer, PayPay, Starbucks, AMD and more

By Proactive 27/10/2023

Pharma & Biotech

Novo Nordisk's Ozempic to take center stage when the pharma giant reports 3Q earnings next week

By Proactive 24/10/2023

Pharma & Biotech

Nestle explores 'companion' food products amid Ozempic and Wegovy's weight loss drug surge

By Proactive 19/10/2023

Pharma & Biotech

Novo Nordisk buys blood pressure treatment to bolster diabetes portfolio

Novo is paying KBP Biosciences US$1.3 billion for ocedurenone

By Proactive 16/10/2023

Pharma & Biotech

Novo Nordisk ups guidance, sees higher sales of Ozempic

By Proactive 13/10/2023

Medical technology & services

Novo Nordisk data knocks $5bn from the value of three leading dialysis companies

By Proactive 11/10/2023

Pharma & Biotech

Eli Lilly gets $14bn boost from Ozempic data - here's what's happened

By Proactive 11/10/2023

Food & drink

Unilever, Danone, Nestle: Impact of weight loss drugs may have ripple effect on European food industry

By Proactive 09/10/2023

Pharma & Biotech

Novo Nordisk's Wegovy and Ozempic US patents to be examined by appeal board

By Proactive 05/10/2023